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Human thioredoxin-1 (TRX) is a 12-kDa protein with redox-active dithiol in the active site
-Cys-Gly-Pro-Cys-. It has been demonstrated that systemic administration and transgenic
overexpression of TRX ameliorate inflammation in various animal models, but its anti-
inflammatory mechanism is not well characterized. We investigated the anti-inflammatory
effects of topically applied recombinant human TRX (rhTRX) in a murine irritant contact
dermatitis (ICD) induced by croton oil. Topically applied rhTRX was distributed only in
the skin tissues under both non-inflammatory and inflammatory conditions, and signifi-
cantly suppressed the inflammatory response by inhibiting the production of cytokines
and chemokines, such as TNF-α, Il-1β, IL-6, CXCL-1, and MCP-1. In an in vitro study, rhTRX
also significantly inhibited the formation of cytokines and chemokines produced by ker-
atinocytes after exposure to croton oil and phorbol 12-myristate 13-acetate. These results
indicate that TRX prevents skin inflammation via the inhibition of local formation of inflam-
matory cytokines and chemokines. As a promising new approach, local application of TRX
may be useful for the treatment of various skin and mucosal inflammatory disorders.
Keywords: thiroredoxin, topical application, cytokines, keratinocytes, phorbol 12-myristate 13-acetate, cutaneous
inflammatory disorders, redox
INTRODUCTION
Thioredoxin-1 (TRX), a small (12-kDa) protein with a highly con-
served redox-active dithiol/disulfide in the active site sequence
Cys32-Gly-Pro-Cys35, plays a variety of redox-related roles in
essentially all organisms on the earth ranging from Escherichia
coli to humans (1). TRX catalyzes reduction of disulfide bonds
and quenches reactive oxygen species (ROS) by coupling with
TRX-dependent peroxidases, or peroxiredoxins. In addition to its
anti-oxidant properties, TRX has a crucial role in the redox reg-
ulation of cellular signaling and activation. TRX is involved in
various redox-dependent cellular processes, such as gene expres-
sion, signal transduction, cell growth, and apoptosis, interacting
with various kinds of target molecules. Secreted TRX has first
been identified as adult T cell leukemia-derived factor produced
by human T-lymphotropic virus type I (HTLV-I)-transformed
T cells (2). Under stress conditions TRX is released into the
extracellular space, where it exerts the cytoprotective effect and
cytokine-like activities (3). Transgenic overexpression of TRX
and the systemic administration of recombinant human thiore-
doxin (rhTRX) are effective in a wide variety of inflammatory
disease models, such as viral pneumonia, acute lung injury, pan-
creatitis, myocarditis, chronic obstructive pulmonary diseases, and
indomethacin-induced gastric injury (4–9).
Indeed, recent reports have demonstrated that allergic con-
tact dermatitis (ACD), the irritant contact dermatitis (ICD) to
croton oil and ultraviolet light-induced dermatitis were unequiv-
ocally suppressed in TRX-transgenic mice (10, 11). Intriguingly,
overproduction of TRX in these mice did not affect the con-
tact hypersensitivity response in the induction phase of ACD,
whereas skin inflammation was suppressed in TRX-transgenic
mice after elicitation challenge with DNFB (10). Similarly, exoge-
nously administered TRX exhibited anti-inflammatory activ-
ity in the effector phase, but not in the sensitizing phase of
ACD. Our previous report has also shown that there were no
apparent differences in immune cell populations between TRX-
transgenic and wild-type animals, suggesting that the suppres-
sion of allergic reaction and inflammation observed in TRX-
transgenic mice may not depend on Th1/Th2 polarization or
systemic immunosuppression (12). These findings indicate that
the anti-inflammatory mechanism of TRX is apparently dif-
ferent from the mechanisms associated with anti-inflammatory
agent such as glucocorticoids, which regulate the inflamma-
tory reaction in association with the suppression of immune
responses. Analyses of TRX-transgenic mice have strongly sug-
gested possible therapeutic utility of TRX for inflammatory
disorders.
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Accumulating evidence indicates that epidermal keratinocytes
play a major role in the initiation of the inflammatory response in
the skin under pathological conditions. Keratinocytes constitute
90% of epidermal cells in the outermost layer of the skin, forming
a barrier against the external stimuli and harmful environmen-
tal agents. Wilmer et al. (13) reported that cultured keratinocytes
produced inflammatory cytokines in response to primary con-
tact irritants including croton oil, and the expression patterns of
cytokines correlated with the onset of skin inflammation. Since
excessive production of inflammatory cytokines would be the
major cause of tissue damages during inflammation, keratinocytes
have been implicated as the primary source of inflammatory
mediators, contributing to the development of skin inflammation.
In this study, the anti-inflammatory effect of topically applied
rhTRX was tested in the well-established model of ICD induced
by croton oil (14, 15).
RESULTS
TOPICAL APPLICATION OF rhTRX SUPPRESSES ICD INDUCED BY
CROTON OIL
Croton oil was applied to both sides of murine ear to induce ICD.
In order to examine the effect of topically applied rhTRX on ICD,
the mice were divided into five groups: (1) a group of mice received
rhTRX 2 h before croton oil application (pre-treatment), (2) a
group of mice received bovine serum albumin (BSA) 2 h before
croton oil application, (3) a group of mice received rhTRX treat-
ment immediately after croton oil application (post-treatment),
(4) a group of mice received BSA immediately after croton oil
treatment, (5) a group of mice received heat-inactivated rhTRX
immediately after croton oil treatment. The degree of ear swelling
was measured 6 and 24 h after croton oil application. As shown
in Figure 1A, both pre- and post-treatment with rhTRX signifi-
cantly suppressed the ear swelling induced by croton oil, compared
to the BSA group (∗ ∗ ∗P< 0.001, Figure 1A, Left and Middle).
Heat-inactivated rhTRX offered no protection against skin inflam-
mation (∗∗P< 0.01, Right). In addition, histological evidence of
skin inflammation, such as edema and infiltration of inflamma-
tory cells including neutrophils and macrophages, was suppressed
by the topical application of rhTRX (Figure 1B). The number of
the infiltrating neutrophils and the caliber of the capillary blood
vessels in the dermis were counted and measured for quantita-
tive analysis to evaluate the anti-inflammatory effect of TRX. The
results showed that the average number of infiltrating neutrophils
and the dilatation of the capillary blood vessels were significantly
decreased in the rhTRX treated group, compared to BSA treated
group (∗ ∗ ∗P< 0.001, ∗ ∗ ∗P< 0.001) (Figure 1C). These results
indicated that topically applied rhTRX suppressed ICD, but rhTRX
lost the anti-inflammatory effect by the heat treatment.
THE EXPRESSION OF TNF-α, IL-1β, IL-6, CXCL-1, MIF, AND MCP-1 WERE
SUPPRESSED BY rhTRX IN ICD INDUCED BY CROTON OIL
We investigated the effect of exogenous TRX on the cytokine pro-
duction in the croton oil-induced ICD model. The expression of
selected cytokines and chemokines in the ear tissues were studied
by immunohistochemical staining conducted 24 h after croton oil
application. TNF-α, IL-1β, IL-6, chemokine (C-X-C motif) ligand
(CXCL)-1, macrophage inhibitory factor (MIF), and monocyte
chemoattractant protein (MCP)-1 were strongly induced and dif-
fusely expressed in epidermis and dermis in the control animals.
In contrast, that expression of these cytokines was all strongly sup-
pressed by the topical application of rhTRX (Figure 2A). We also
determined the mRNA expression of these cytokines by real-time
RT-PCR 24 h after croton oil treatment. We used RNA extracted
from the skin of the back of the mice, because the amount of RNA
that can be extracted from the skin of the ears is so low that it
cannot be used for quantitative analysis. The mRNA expression of
TNF-α, IL-1β, IL-6, CXCL-1, and MCP-1 were significantly sup-
pressed in the TRX treated group, compared to the BSA treated
group (∗∗P< 0.01, ∗P< 0.05) (Figure 2B). These results suggested
that topically applied rhTRX suppressed ICD by inhibiting the
production of the inflammatory cytokines and chemokines.
PHARMACOKINETICS OF TOPICALLY APPLIED rhTRX
Next we examined the distribution of topically applied rhTRX in
murine skin tissues under non-inflammatory and inflammatory
conditions. Twenty micrograms per milliliter rhTRX was applied
on the surface of the murine ears, and ear specimens were stained
with anti-human monoclonal TRX antibody. The anti-TRX anti-
bodies do not cross-react with the mouse TRX, verifying that
only exogenously applied rhTRX was detected in the histological
analysis. rhTRX was distributed in the epidermis and cutaneous
appendages under non-inflammatory conditions (Figure 3A). In
contrast, rhTRX was distributed in both the epidermis and the
dermis under inflammatory condition (Figure 3B). No rhTRX
was detected by ELISA in the blood or the urine 6 and 24 h
after it was applied under either non-inflammatory or inflamma-
tory conditions (data not shown). These findings indicated that
topically applied rhTRX penetrates into skin tissue to exert its
anti-inflammatory effect on ICD, but it does not diffuse into the
circulation.
rhTRX SUPPRESSED CROTON OIL-INDUCED EXPRESSION OF TNF-α,
IL-1β, IL-6, CXCL-1, AND MCP-1 mRNA IN CULTURED MURINE
KERATINOCYTES
As shown in Figure 2, the cytokines were diffusely expressed in the
epidermis, suggesting that the cytokines were possibly produced by
keratinocyte in the ICD mice model. Therefore we selected murine
keratinocytes (PAM 212 cells), as the target to detect the effect of
TRX on the production of cytokines after croton oil treatment.
In order to investigate the optimal concentration of croton
oil which induces the production of cytokines by PAM 212 cells,
the cell viability was assessed by a lactate dehydrogenase (LDH)
release assay 24 h after croton oil treatment. The application
of 2–60µg/ml croton oil did not cause cell damage (data not
shown). Therefore, 20µg/ml croton oil was selected for subse-
quent experiments. The cell lines were incubated with varying
amounts of rhTRX immediately after croton oil treatment. The
mRNA expression of TNF-α, IL-1β, IL-6, CXCL-1, and MCP-1
was determined by real-time RT-PCR 24 h after the addition of
croton oil. The results indicate that the expression of the cytokines
and chemokines was significantly suppressed by the addition of
2–20µg/ml rhTRX. P values in 2–20µg/ml rhTRX treatment
groups are shown as follows: (∗ ∗ ∗P< 0.001,∗∗P< 0.01,∗P< 0.05)
(Figure 4). In order to detect the time course of the effects of
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FIGURE 1 |The topical application of rhTRX strongly suppressed
ICD. (A) Inflammatory reactions were expressed as the average
increase in ear swelling. Both pre- and post-treatment with rhTRX
significantly suppressed ear swelling at 6 and 24 h after croton oil was
applied (***P< 0.001, **P< 0.01). Values are the mean SD of each
group (Student t -test). Left, Middle: n=5, Right: n=3. (B)
Representative pictures of hematoxylin and eosin staining of the ears.
The infiltrating neutrophil and edema were suppressed in both pre- and
post-treatment in the rhTRX topical application group, compared with
the control group. Acetone/olive oil was used as a vehicle control. Bars,
50µm. The infiltrating neutrophils were indicated by arrows (Bar,
100µm). (C) The average number of infiltrating neutrophil in the dermis
and the dilatation of the capillary blood vessels were significantly
reduced in the post-treatment rhTRX group, compared with the control
group (***P<0.001). Data are expressed as the mean±SD of five
mice per group (Student t -test).
TRX, 10µg/ml rhTRX was added to the culture medium, imme-
diately after 20µg/ml croton oil was applied, and incubated for
6, 24, and 48 h, respectively. In control cells, the expression levels
of these cytokines were increased within 6 h in response to croton
oil, and returned to the basal levels at 48 h post stimulation. Eleva-
tion of these inflammatory cytokines was significantly suppressed
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in the presence of rhTRX. P values in the groups which treat
with rhTRX 6 and 24 h later are shown as follows: (∗ ∗ ∗P< 0.001,
∗∗P< 0.01, ∗P< 0.05) (Figure 5). These findings indicate that
rhTRX suppresses the mRNA expression of cytokines produced
by keratinocytes.
rhTRX SUPPRESSED THE RELEASE OF TNF-α, IL-6, AND MCP-1 BY
MURINE KERATINOCYTES, AFTER STIMULATION WITH CROTON OIL
In order to investigate whether rhTRX suppresses the release of
the cytokines from PAM 212 cell into culture medium, 10µg/ml
rhTRX was added to the culture medium immediately after the
addition of croton oil, and a Cytometric Bead Array analysis was
conducted to quantify the concentrations of TNF-α, IL-6, and
MCP-1 in the culture supernatant 24 h after the addition of cro-
ton oil. We have demonstrated that the concentration of applied
croton oil did not affect the cell viability. The accumulation of
TNF-α, IL-6, and MCP-1 in the culture supernatant was signifi-
cantly suppressed by the application of rhTRX, compared to BSA
(∗P< 0.05) (Figure 6). These results indicate that rhTRX could act
on keratinocytes to prevent the production and release of cytokines
induced by croton oil.
PMA-INDUCED TNF-α PRODUCTION WAS SUPPRESSED BY rhTRX IN
CULTURED MURINE KERATINOCYTES
We investigated the effect of rhTRX on the PMA-induced produc-
tion of TNF-α in PAM 212 cells. Ten micrograms per milliliter
rhTRX was added immediately after PMA treatment, and then
incubated for 6 h for real-time RT-PCR analysis. The mRNA
expression of TNF-α in the rhTRX treatment group was sig-
nificantly suppressed, compared with the BSA treatment group
(∗P< 0.05) (Figure 7A). The cells were also incubated for 24 h
for an immunocytochemical study, because the production of
protein is slower than the production of mRNA. TNF-α was
strongly expressed in the PMA and PMA+BSA treatment groups,
whereas the expression of TNF-α was strongly inhibited by the
rhTRX application (Figure 7B). These findings clearly showed
that cytokines are produced by keratinocytes, and suppressed by
rhTRX application.
DISCUSSION
Functioning as intercellular mediators, cytokines are produced
by lymphocytes as well as by effector cells during inflammatory
responses. Particularly, IL-1 and TNF-α have been implicated in
FIGURE 2 | Continued
Frontiers in Immunology | Inflammation September 2013 | Volume 4 | Article 269 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tian et al. Thioredoxin suppresses cytokine production
FIGURE 2 |The topical application of rhTRX suppressed the expression
ofTNF-α, IL-1β, IL-6, CXCL-1, MIF, and MCP-1 in the ICD model induced by
croton oil. (A) Immunohistochemistry and real-time RT-PCR were performed
to detect the effect of rhTRX on the production of the cytokines. The results
of imunohistochemical staining show the expression of the cytokines. The
expression of TNF-α, IL-1β, IL-6, IL-8, MIF, and MCP-1 was strongly suppressed
by the topical application of rhTRX. Bars, 50µm. (B) Induction of TNF-α, IL-1β,
IL-6, CXCL-1, and MCP-1 were verified by real-time RT-PCR. The mRNA
expression was normalized to GAPDH. The mRNA expression levels were
determined relative to control sample from BSA treatment group. The mRNA
expression of TNF-α, IL-1β, IL-6, CXCL-1, and MCP-1 was significantly
suppressed by the topical application of rhTRX (*P<0.05, **P<0.01). Values
are mean±SD of five mice per group (Student t -test, Wilcoxon signed-rank
test).
many diseases including ICD, which accounts for 20–80% of all
cases of contact dermatitis depending on the country (16, 17). In
addition, as an immune mechanism in the pathogenesis of ICD,
it has become quite clear that exposure to various irritant exerts
toxic effects on keratinocytes, activating innate immunity with
the release of TNF-α, IL-1β, IL-6, and IL-8 from keratinocytes
(17–19). In turn, the cytokines activate Langerhans cells, dermal
dendritic cells, and endothelial cells, all of which contribute to
cellular recruitment to the site of the keratinocyte damage. In
ICD as well as ACD, infiltrating cells include neutrophils, lym-
phocytes, macrophages, and mast cells, which further promote the
inflammatory cascade (17–19). These data strongly suggest that
keratinocytes play a major role in the pathogenesis of ICD. In this
study, we used the well-established model of ICD induced by cro-
ton oil, of which major active component is PMA (15). It has been
reported that topically applied croton oil or PMA-induced pro-
duction of cytokines and chemokines such as TNF-α, IL-1β, IL-6,
and CXCL-1 in murine skin (13, 20). We also demonstrated that
not only TNF-α, IL-1β, IL-6, and CXCL-1, but also MCP-1 were
highly induced in the region of skin epidermis mainly composed of
keratinocytes after treatment with croton oil (Figure 2). Further-
more, both our in vitro study and the previous study showed that
the cytokines and chemokines were produced by the keratinocytes
stimulated with croton oil or PMA. Although our results would
not exclude possible involvement of cellular factors other than ker-
atinocytes, our results, together with previous studies in the litera-
ture (13,21,22), strongly suggest that keratinocytes are the primary
source of the inflammatory mediators in the murine ICD model.
Several explanations of the anti-inflammatory effects of TRX
have been reported: (a) anti-oxidant effect (2), (b) anti-leukocyte
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FIGURE 3 | rhTRX was distributed only in the epidermis in mice
without croton oil stimulation, but it was distributed in both the
epidermis and dermis in irritant dermatitis. (A) rhTRX was only
distributed in the epidermis and cutaneous appendages at 6 and 24 h in
the mice without the croton oil stimulation. Bars, 100µm (n=5). (B) After
croton oil was applied, the rhTRX was distributed in both the epidermis
and dermis in irritant dermatitis in the group with the rhTRX pre-treatment
at 24 h. Bars, 50µm (n=5).
chemotaxis (3), (c) suppression of neutrophil adhesion on
endothelial cells through membrane TRX-1 (5), (d) suppres-
sion of complement activation, and (e) inhibition of the MIF
(23, 24). In this study, we demonstrated that topically applied
rhTRX suppressed the production of inflammatory cytokines
and chemokines, which would more likely explain the protective
effects of TRX under inflammatory conditions, in addition to anti-
leukocyte chemotaxis. Previous reports have shown that exoge-
nous TRX suppresses the production of cytokines and chemokines
in some diseases, such as myosin-induced autoimmune myocardi-
tis (7), indomethacin-induced gastric injury (9), and influenza A
virus induced acute lung injury (25). These findings also strongly
support the concept that attenuation of cytokine production is
one of the mechanisms underlying the anti-inflammatory effect of
TRX. It has been reported that exogenously administered human
TRX suppresses lipopolysaccharide-induced neutrophil recruit-
ment (23). We also demonstrated that topical application of
rhTRX suppressed the infiltration of neutrophils to dermal tissues,
where the chemotactic factors such as CXCL-1 and MCP-1 were
decreased (Figure 2A). We suppose that rhTRX inhibited the pro-
duction of these chemokines by keratinocytes in inflammatory dis-
orders such as ICD and ACD, thereby suppressing the neutrophils
chemotaxis. Taken together,all of these findings suggest that exoge-
nous TRX suppresses inflammatory reactions by inhibiting the
production of cytokines and chemokines. In addition to croton
oil and PMA, we also used polyriboinosinic-polyribocytidilic acid
(polyI: C), an immunostimulant known to interact with toll-like
receptor (TLR) 3, to investigate the anti-inflammatory effects of
TRX. TRX suppressed the production of IL-33 and CXCL-1 by
PAM 212 cells induced by polyI: C (data not shown), indicating
that virus-associated immune responses in keratinocytes, as well
as PMA-induced inflammation, can be regulated by TRX applied
exogenously.
It is unclear how extracellular TRX regulates inflamma-
tory processes. Accumulating evidence indicates that oxidative
stress is associated with inflammation, and thiol anti-oxidants,
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FIGURE 4 |The application of rhTRX significantly suppressed the mRNA
expression ofTNF-α, IL-1β, IL-6, CXCL-1, and MCP-1 in PAM 212 cells
stimulated by croton oil. Croton oil was added to the culture medium in the
presence or absence of rhTRX (2–20µg/ml). The mRNA expression of TNF-α,
IL-1β, IL-6, CXCL-1, and MCP-1 were measured by real-time RT-PCR 24 h after
stimulation. The mRNA expression in the rhTRX treatment group was
significantly suppressed by 2–20µg/ml rhTRX, compared with the BSA
treatment groups. The mRNA expression levels were determined relative to
croton oil-stimulated cells. Values are shown as the mean±SD of three
experiments (*P<0.05, **P< 0.01, ***P<0.001) (Student t -test).
especially glutathione, have often been thought of as possible
anti-inflammatory mediator (26). Indeed, oxidative stress plays
an important role in many inflammatory diseases, including ICD
(27–29). A molecular mechanism for this association was first pro-
vided in 1991, with the finding that H2O2 activates the transcrip-
tion factor NF-κB, which is involved in the production of many
inflammatory cytokines, while thiol anti-oxidants inhibit its acti-
vation (30). Several studies have reported inhibition of cytokine
production by many thiol anti-oxidants. As a redox regulatory
protein, TRX can scavenge ROS, either directly or in cooperation
with peroxiredoxin (24). Given that oxidative stress is induced
by treatment with croton oil in murine skin (31, 32), TRX might
reduce the cellular oxidative stress under inflammatory conditions,
which would contribute to the suppression of the ROS depen-
dent activation of inflammatory signaling. Actually, it has been
reported that extracellular TRX inhibited LPS-induced activation
of the NF-κB pathway in cultured macrophages (33), which could
be involved in the down-regulation of inflammatory cytokines,
including IL-1β, IL-6, IL-8, and TNF-α. Alternatively, extracellu-
lar TRX may suppress the activation of inflammatory signaling by
acting on cell surface molecules to control their function through
its reduction activity. Exogenously applied TRX was associated
with lipid rafts (34), which are specialized membrane domains
enriched in cholesterol and glycosphingolipids (35). Since lipid
rafts serve as a membrane platform for the assembly of signaling
complexes, extracellular TRX may interact with the components
of lipid rafts and modulate the redox properties on the cell surface,
potentially leading to dynamic changes in the cellular response to
inflammatory stimuli.
It was also suggested that extracellular thioredoxin could be
transported into cells through membrane lipid rafts (34, 36), and
control intracellular redox balance. As an endogenous negative
regulator of thioredoxin, thioredoxin-binding protein-2 (TBP-2)
directly binds thioredoxin to inhibit thioredoxin-reducing activ-
ity (37). We propose a redox-sensitive signaling complex named
redoxisome (38), comprising TRX and TBP-2, which regulates a
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FIGURE 5 |The application of rhTRX can suppress the mRNA
expression of cytokines and chemokines in PAM 212 cells after croton
oil stimulation for at least 24 h. After croton oil stimulation, the mRNA
expression of TNF-α, IL-1β, IL-6, CXCL-1, and MCP-1 was measured by
real-time RT-PCR at the indicated time points. Application of 10µg/ml rhTRX
significantly suppressed the mRNA expression of the cytokines and the
chemokines at 6 and 24 h after the croton oil was applied. The mRNA
expression levels were determined relative to croton oil-stimulated cells.
Values are shown as the mean±SD of three experiments (*P<0.05,
**P<0.01, ***P<0.001) (Student t -test).
great variety of redox-sensitive signals. Thus we suppose that the
redox-dependent signalosome may be involved in the regulation of
inflammatory pathway. It was reported that TBP-2 deficiency pro-
motes TNF-α-induced NF-κB activity (39). TBP-2-/- mice injected
with LPS did not show higher serum levels of TNF-α, IL-6, IL-10,
Interferon (IFN)-β, IFN-γ, MCP-1, or macrophage inflamma-
tory protein-2 (MIP-2), compared with wild-type mice (40). As
our next strategic aim, we will conduct a study on the mole-
cular mechanism of extracellular TRX for suppressing cytokine
production.
Here we demonstrated that the topical application of rhTRX
is very effective for treatment of ICD by suppressing the produc-
tion of cytokines and chemokines, and topically applied rhTRX
was distributed limitedly in the skin, but not the blood or the
urine. Because topical application would be more practical and
safe in clinical medicine, compared to internal administration
or injections, this finding was quite meaningful and novel. Our
study also showed that both pre- and post-treatment with rhTRX
significantly suppressed ICD response, indicating that the topical
application of rhTRX can have a promising effect on not only pro-
phylactic but also therapeutic medicine. In addition, our results
suggest that rhTRX has a direct effect on keratinocytes widely dis-
tributed throughout the dermatitis lesion. Taken together, these
findings suggest that TRX could be a useful, near ideal agent for
the treatment of dermatitis.
In conclusion, we demonstrated that the topical application of
rhTRX suppressed ICD by inhibiting the production and release
of cytokines and chemokines. One might expect that TRX is useful
for the treatment of a variety of skin and mucosal inflammatory
disorders.
MATERIALS AND METHODS
MICE
Wild-type female C57BL6 mice (8 weeks old) were purchased
from Charles River Japan (Tokyo, Japan). All animals were main-
tained in microisolator cages and exposed to a 12-h light/12 h
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FIGURE 6 | After stimulation with croton oil, rhTRX suppressed the
release ofTNF-α, IL-6, and MCP-1 by PAM 212 cells into the medium. PAM
212 cells were left untreated (no croton oil) or stimulated with croton oil in the
presence of BSA or rhTRX (10µg/ml). The concentrations of TNF-α, IL-6, and
MCP-1 in the culture supernatant were measured by CBA assay 24 h after
croton oil treatment. The concentrations of TNF-α, IL-6, and MCP-1 were
significantly lower than those shown in the BSA application group (*P<0.05).
Values are shown as the mean±SD of the samples (Student t -test).
dark cycle, with standard feed and water ad libitum. All experi-
ments were conducted according to the Institutional guidelines
and regulations.
ICD MODEL
In order to induce ICD, 10µl of 2% croton oil (Sigma, St. Louis,
MO, USA) dissolved in acetone/olive oil (4:1) was applied to the
dorsal and ventral aspects of both sides of the murine ears and
back. Ear swelling was measured in a blinded fashion with a digi-
matic micrometer (Mitutoyo, Tokyo, Japan), 6 or 24 h after the
croton oil treatment. The mice were euthanized immediately after
the experiment was concluded, and the target tissue samples were
removed.
TOPICAL APPLICATION OF rhTRX
Twenty micrograms per milliliter rhTRX in phosphate-buffered
saline (PBS) (Redox Bio Science, Japan) was topically applied
by the nano-spray machine (quantity of mist: 1 ml/min) on the
dorsal and ventral aspects of the ears and the back (5 s, distance
10 cm) (Konishi Seiko Japan), and 20µg/ml of BSA was applied as
www.frontiersin.org September 2013 | Volume 4 | Article 269 | 9
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FIGURE 7 | After stimulation with phorbol 12-myristate 13-acetate
(PMA), rhTRX suppressed the expression ofTNF-α produced by murine
keratinocytes. (A) Ten nanomolar PMA was added to the medium, and cells
were incubated for 6 h. The mRNA expression levels of TNF-α were
determined by real-time RT-PCR. The TNF-α mRNA expression was
significantly suppressed by 10µg/ml rhTRX (*P<0.05). The mRNA
expression levels were determined relative to PMA-stimulated cells. Values
are shown as the mean±SD of two experiments (Student t -test). (B) The
expression of TNF-α in the cells was detected by immunocytochemistry 24 h
after simulation. The application of 10µg/ml rhTRX significantly suppressed
the expression of TNF-α produced by PAM 212 cells stimulated by PMA
(expression of TNF-α, FITC, green; nuclear staining, DAPI, blue). Bars, 100µm.
a control. rhTRX was denatured at 100°C for 20 min. About 1.7µg
of rhTRX was applied to the entire surface of mouse ear (about
1 cm2).
HISTOLOGICAL ANALYSIS OF ICD
The ears were fixed in formalin for 24 h, embedded in paraffin, and
stained with hematoxylin and eosin. The numbers of neutrophils
in the dermis were counted for a quantitative analysis in 10 micro-
scopic fields of 5 different specimens, and the average number of
neutrophils was obtained. The caliber of the capillary blood vessels
was measured as a quantitative indication of the dilatation of the
capillary blood vessels. The caliber sizes of 20 randomized vessels
in the dermis and the subcutaneous tissues from both the TRX and
BSA treatment groups were measured by microscope, in order to
obtain the average size.
IMMUNOHISTOCHEMISTRY
Briefly, tissue samples were prepared as 3 µm-thick sections from
paraffin-embedded specimens, followed by deparaffinization and
blocking of endogenous peroxidase activity with 3% hydrogen
peroxide in methanol for 15 min, and 10% bovine serum was
added for 30 min to block non-specific binding at room tempera-
ture. The tissue specimens were incubated with one of the rabbit
anti-mouse TNF-α polyclonal antibody (Hycult Biotech), goat
anti-mouse IL-1β antibody (R and D systems), goat anti-mouse
IL-6 polyclonal antibody (Santa Cruz Biotechnology), goat anti-
mouse CXCL-1 polyclonal antibody (R and D Systems), anti-MIF
polyclonal antibody (Invitrogen), rat anti-mouse MCP-1 mono-
clonal antibody (Hycult Biotech), and mouse anti-human mono-
clonal TRX antibody (Redox Bio Science) as primary antibodies
overnight at 4°C. After being washed with PBS, sections were
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incubated with a biotinylated anti-rabbit immunoglobulin for
TNF-α (Dako), biotinylated anti-goat immunoglobulin for IL-1β,
IL-6, and CXCL-1 (Dako), biotinylated anti-rat immunoglobulin
for MIF and MCP-1 (Dako) for 30 min, followed by streptavidin-
conjugated horseradish peroxidase (Dako) for 30 min at room
temperature. The specimens, incubated with mouse anti-human
TRX monoclonal antibody, were treated at room temperature
with a Histofine® mouse stain kit (Nichirei Corporation) to block
non-specific binding, then with 3,3′-diaminobenzidine working
solution (Vector Laboratories, Burlingame CA, USA).
CELL CULTURE AND CELL TREATMENT
A spontaneously transformed BALB/c keratinocyte cell line, PAM
212, obtained from Dr. Steve Uilric (Department of Immunology,
MD Anderson Cancer Center, Houston, TX, USA), was used in
the study. Cells were maintained in RPMI 1640 (Sigma chem-
ical) supplemented with heat-inactivated 10% FBS (Hyclone),
Hepes (10 mM) (Sigma), 1% non-essential amino acids (Sigma),
l-glutamine (2 mM), sodium pyruvate (1 mM) (Sigma), 100 U/ml
penicillin (Sigma), 100µg/ml streptomucin (Sigma), 0.25µg/ml
amphotericin B (Sigma), and 2-mercaptoethanol (Sigma).
Cells were cultured at 37°C in 95% air/5% CO2. PAM 212
cells in passage 1–3 were seeded into six well plates at a density
of 2× 105/2 ml medium per well and cultured for 24 h. Twenty
micrograms per milliliter croton oil/0.1% ethanol (13) or 10 nM
PMA (41) was added to the medium in the presence or absence of
rhTRX (0–20µg/ml).
REAL-TIME RT-PCR ANALYSIS
Total RNA was extracted using a QuickGene RNA tissue kit SII
(Fujifilm, Tokyo, Japan) for the tissue, and a QuickGene RNA
cultured cell kit SII (Fujifilm, Tokyo, Japan) for the cells. Total
RNA was reverse transcribed using the PrimeScript RT Reagent
Kit (Takara, Shiga, Japan). A real-time PCR was performed using
the SYBR® Premix Ex Taq™ II (Takara, Shiga, Japan). All primers
were purchased from Takara Bio, and Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was used as the housekeeping gene. The
reaction was performed with ABI PRISM 7500 Sequence Detec-
tion System (Applied Bio Systems, Tokyo, Japan) to quantify the
mRNA, according to the manufacturer’s protocol.
CYTOMETRIC BEAD ARRAY ANALYSIS
The concentration of IL-6, MCP-1, and TNF-α in the culture
supernatant of the PAM 212 cells was measured using the BD
Cytometric Bead Array mouse inflammation kit (BD Biosciences),
following the manufacturer’s protocol.
IMMUNOCYTOCHEMISTRY
The samples were fixed in cold methanol for 20 min, and incu-
bated for 10 min with PBS containing 0.25% Triton X-100 for
permeabilization. One percent BSA in PBS was added for 30 min
to block unspecific binding of the antibodies. The samples
were incubated with rabbit anti-mouse TNF-α antibody (Hycult
Biotech) overnight at 4°C. Biotinylated anti-rabbit immunoglob-
ulin (Dako) was added for 1 h at room temperature. Strepta-
vidin/FITC (Dako) was added for 30 min in the dark, the sam-
ples were then incubated with 1µg/ml DAPI for 1 min for DNA
staining (Invitrogen).
STATISTICAL ANALYSIS
Results were expressed as mean± SD. After the data were tested
for normal distribution using the Shapiro–Wilk test, the normal
distributed data were evaluated by the Student t -test for compar-
isons between two groups, and the non-normal distributed data
was tested by Wilcoxon signed-rank test. Findings of P< 0.05 were
considered statistically significant.
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